X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of agreement, OncoArendi will confirm certain properties of a series of selective small molecule inhibitors targeting this novel therapeutic target in fibrosis. OncoArendi will then have the option to obtain rights for a worldwide license to these inhibitors.
Lead Product(s): Undisclosed
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: University of Michigan
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 11, 2022
Details:
OncoArendi Therapeutics gains global development and commercialization rights of OncoArendi’s OATD-01. OATD-01 is a Phase 2-ready chitotriosidase/acidic mammalian chitinase inhibitor to treat Idiopathic pulmonary fibrosis and other diseases with a fibrotic component.
Lead Product(s): OATD-01
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: OATD-01
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Galapagos
Deal Size: $380.8 million Upfront Cash: $29.7 million
Deal Type: Licensing Agreement November 05, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
